{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:42:56Z","timestamp":1791614576000,"version":"4.3.4"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"DOI":"10.2146\/ajhp140732","type":"journal-article","created":{"date-parts":[[2015,5,18]],"date-time":"2015-05-18T23:09:42Z","timestamp":1431990582000},"page":"923-929","source":"Crossref","is-referenced-by-count":6,"title":["Oral acetylcysteine for neuropsychiatric disorders"],"prefix":"10.1093","volume":"72","author":[{"given":"Rebecca","family":"Racz","sequence":"first","affiliation":[{"name":"College of Pharmacy University of Michigan (UM) Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burgunda V.","family":"Sweet","sequence":"additional","affiliation":[{"name":"UM Health System and College of Pharmacy Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Sohoni","sequence":"additional","affiliation":[{"name":"St. Mary Mercy Outpatient Psychiatric Services Saint Joseph Mercy Health System Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041604584199400_b1-0720923","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tips.2013.01.001","article-title":"The promise of N-acetylcysteine in neuropsychiatry","volume":"34","author":"Berk","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"2019041604584199400_b2-0720923","first-page":"10","article-title":"Getting a knack for NAC: N-acetyl-cysteine","volume":"8","author":"Sansone","year":"2011","journal-title":"Innov Clin Neurosci"},{"key":"2019041604584199400_b3-0720923","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/07315724.1986.10720121","article-title":"Intracellular cysteine and glutathione delivery systems","volume":"5","author":"Meister","year":"1986","journal-title":"J Am Coll Nutr"},{"key":"2019041604584199400_b4-0720923","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s11064-012-0775-4","article-title":"Brain region-specific glutathione redox imbalance in autism","volume":"37","author":"Chauhan","year":"2012","journal-title":"Neurochem Res"},{"key":"2019041604584199400_b5-0720923","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1016\/j.bbagen.2013.04.016","article-title":"The chemistry and biological activities of N-acetylcysteine","volume":"1830","author":"Samuni","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"2019041604584199400_b6-0720923","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-244X-13-196","article-title":"A randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders","volume":"13","author":"Ghanizadeh","year":"2013","journal-title":"BMC Psychiatry"},{"key":"2019041604584199400_b7-0720923","first-page":"985","article-title":"N-acetylcysteine for treatment of autism, a case report","volume":"17","author":"Ghanizadeh","year":"2012","journal-title":"J Res Med Sci"},{"key":"2019041604584199400_b8-0720923","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A randomized controlled pilot trial of oral N-acetylcysteine in children with autism","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiatry"},{"key":"2019041604584199400_b9-0720923","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/sj.mp.4000979","article-title":"Linkage and association of the glutamate receptor 6 gene with autism","volume":"7","author":"Jamain","year":"2002","journal-title":"Mol Psychiatry"},{"key":"2019041604584199400_b10-0720923","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1136\/jmg.40.4.e42","article-title":"The metabotropic glutamate receptor 8 gene at 7q31: partial duplication and possible association with autism","volume":"40","author":"Serajee","year":"2003","journal-title":"J Med Genet"},{"key":"2019041604584199400_b11-0720923","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/10937400600882079","article-title":"Evidence of toxicity, oxidative stress, and neuronal insult in autism","volume":"9","author":"Kern","year":"2006","journal-title":"J Toxicol Environ Health Part B Crit Rev"},{"key":"2019041604584199400_b12-0720923","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12011-010-8840-9","article-title":"Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation","volume":"143","author":"Meguid","year":"2011","journal-title":"Biol Trace Elem Res"},{"key":"2019041604584199400_b13-0720923","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1034\/j.1601-183X.2003.00037.x","article-title":"Model of autism: increased ratio of excitation\/inhibition in key neural systems","volume":"2","author":"Rubenstein","year":"2003","journal-title":"Genes Brain Behav"},{"key":"2019041604584199400_b14-0720923","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/cap.2013.0137","article-title":"N-acetylcysteine as treatment for self-injurious behavior in a child with autism","volume":"24","author":"Marler","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2019041604584199400_b15-0720923","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jocrd.2012.10.003","article-title":"N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: a case series","volume":"2","author":"Van Ameringen","year":"2013","journal-title":"J Obsessive-Compulsive Relat Disord"},{"key":"2019041604584199400_b16-0720923","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","article-title":"N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Afshar","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"2019041604584199400_b17-0720923","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","article-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder","volume":"184","author":"Lafleur","year":"2006","journal-title":"Psychopharmacology"},{"key":"2019041604584199400_b18-0720923","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger","year":"2011","journal-title":"Pharmacol Ther"},{"key":"2019041604584199400_b19-0720923","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.npp.1300733","article-title":"Glutamatergic dysfunction in OCD","volume":"30","author":"Chakrabarty","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"2019041604584199400_b20-0720923","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/01.jcp.0000264976.86990.00","article-title":"N-acetyl cysteine in the treatment of grooming disorders","volume":"27","author":"Odlaug","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"2019041604584199400_b21-0720923","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/0974-7753.100090","article-title":"N-acetylcysteine in the treatment of trichotillomania","volume":"4","author":"Rodrigues-Barata","year":"2012","journal-title":"Int J Trichology"},{"key":"2019041604584199400_b22-0720923","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/bjd.13080","article-title":"N-acetylcysteine in trichotillomania\u2014a panacea for compulsive skin disorders?","volume":"171","author":"Taylor","year":"2014","journal-title":"Br J Dermatol"},{"key":"2019041604584199400_b23-0720923","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archgenpsychiatry.2009.60","article-title":"N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study","volume":"66","author":"Grant","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"2019041604584199400_b24-0720923","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jaac.2012.12.020","article-title":"N-acetylcysteine in the treatment of pe-diatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial","volume":"52","author":"Bloch","year":"2013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2019041604584199400_b25-0720923","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1741-7015-10-91","article-title":"Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial","volume":"10","author":"Berk","year":"2012","journal-title":"BMC Med"},{"key":"2019041604584199400_b26-0720923","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jad.2011.06.005","article-title":"The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial","volume":"135","author":"Berk","year":"2011","journal-title":"J Affect Disord"},{"key":"2019041604584199400_b27-0720923","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.psychres.2006.04.013","article-title":"Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder\u2014a postmortem study","volume":"151","author":"Michel","year":"2007","journal-title":"Psychiatry Res"},{"key":"2019041604584199400_b28-0720923","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1503\/jpn.100057","article-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action","volume":"36","author":"Dean","year":"2011","journal-title":"J Psychiatry Neurosci"},{"key":"2019041604584199400_b29-0720923","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.biopsych.2008.04.022","article-title":"N-acetyl cysteine for depressive symptoms in bipolar disorder\u2014a double-blind randomized placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol Psychiatry"},{"key":"2019041604584199400_b30-0720923","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1440-1819.2012.02392.x","article-title":"Effects of N-acetyl cysteine on cognitive function in bipolar disorder","volume":"66","author":"Dean","year":"2012","journal-title":"Psychiatry Clin Neurosci"},{"key":"2019041604584199400_b31-0720923","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1590\/S1516-44462011000400011","article-title":"N-acetylcysteine for major depressive episodes in bipolar disorder","volume":"33","author":"Magalhaes","year":"2011","journal-title":"Rev Bras Psiquiatr"},{"key":"2019041604584199400_b32-0720923","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jad.2010.08.001","article-title":"N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial","volume":"129","author":"Magalhaes","year":"2011","journal-title":"J Affect Disord"},{"key":"2019041604584199400_b33-0720923","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/0004867413481631","article-title":"A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania","volume":"47","author":"Da Silva Magalhaes","year":"2013","journal-title":"Aust N Z J Psychiatry"},{"key":"2019041604584199400_b34-0720923","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1515\/revneuro-2012-0039","article-title":"N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals","volume":"23","author":"Asevedo","year":"2012","journal-title":"Rev Neurosci"},{"key":"2019041604584199400_b35-0720923","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"2019041604584199400_b36-0720923","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-244X-11-124","article-title":"Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients","volume":"11","author":"Raffa","year":"2011","journal-title":"BMC Psychiatry"},{"key":"2019041604584199400_b37-0720923","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pnpbp.2013.03.003","article-title":"Oxidative stress and therapeutic implications in psychiatric disorders","volume":"46","author":"Zhang","year":"2013","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2019041604584199400_b38-0720923","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia\u2014a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol Psychiatry"},{"key":"2019041604584199400_b39-0720923","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/sj.npp.1301624","article-title":"Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients","volume":"33","author":"Lavoie","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"2019041604584199400_b40-0720923","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1080\/15622970903144004","article-title":"Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia","volume":"10","author":"Bulut","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"2019041604584199400_b41-0720923","doi-asserted-by":"crossref","first-page":"e29341","DOI":"10.1371\/journal.pone.0029341","article-title":"Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial","volume":"7","author":"Carmeli","year":"2012","journal-title":"PLoS ONE"},{"key":"2019041604584199400_b42-0720923","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WNF.0000000000000001","article-title":"N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, doubleblind, placebo-controlled study","volume":"36","author":"Farokhnia","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"2019041604584199400_b43-0720923","unstructured":"Food and Drug Administration. Dietary supplements (updated December 18, 2014). www.fda.gov\/Food\/DietarySupplements\/default.htm (accessed 2014 May 22)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/72\/11\/923\/28451172\/ajhp0923.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T08:59:18Z","timestamp":1555405158000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/72\/11\/923\/5111343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140732","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,6,1]]},"published":{"date-parts":[[2015,6,1]]}}}